FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a new two-layer pharmaceutical dosage form of tablets for use in the treatment of HIV. A tablet contains dolutegravir, the HIV integrase strand transfer inhibitor together with lamivudine, nucleoside reverse transcriptase inhibitor.
EFFECT: obtaining two-layer pharmaceutical dosage form of tablets.
6 cl, 2 dwg, 6 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING INTEGRASE INHIBITOR | 2010 |
|
RU2602865C2 |
COMBINATION, ITS APPLICATION AND METHODS FOR TREATMENT USING SPECIFIED COMBINATION | 2018 |
|
RU2755710C2 |
PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIRETROVIRAL DRUG AND PHARMACOKINETICS IMPROVER | 2017 |
|
RU2745204C2 |
CENICRIVIROC COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2014 |
|
RU2633069C2 |
PHARMACEUTICAL ANTIRETROVIRAL COMPOSITION | 2013 |
|
RU2648457C2 |
PHARMACEUTICAL COMPOSITIONS CONTAINING DORAVIRINE, TENOFOVIR DISOPROXIL FUMARATE AND LAMIVUDINE | 2016 |
|
RU2736941C2 |
MEDICINE DELIVERY REGULATED SYSTEM CONTAINED IN STOMACH | 2002 |
|
RU2325152C2 |
PHARMACEUTICAL COMPOSITION CONTAINING AMLODIPINE AND LOSARTAN | 2007 |
|
RU2401107C2 |
TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | 2004 |
|
RU2380093C2 |
PHARMACEUTICAL COMPOSITION CONTAINING OLMESARTAN MEDOXOMIL AND ROSUVASTATIN OR ITS SALT | 2013 |
|
RU2616516C2 |
Authors
Dates
2023-09-05—Published
2018-10-08—Filed